Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
09/2003
09/09/2003US6617145 Enzymatic protein for use in treatment of thrombosis
09/09/2003US6617135 Multiple cytokine protein complexes
09/09/2003US6617128 Nucleotide sequences coding proteins for use in prevention of bacteria infection; for use in treatment of gonorrhea
09/09/2003US6617110 Cultured cell comprising a nucleic acid sequence, encoding the protein, that hybridizes to a polynucleotide of given sequence; use to determine if drug is cytotoxic; can use as anticarcinogenic agent
09/09/2003US6616943 Composition comprising Wenguanguo extracts and methods for preparing same
09/09/2003US6616931 Containing sugar; phosphate; carboxylate; recombinant human serum albumin or a nonionic surfactant
09/09/2003US6616930 Peptide fragment of respiratory syncytial virus protein G, immunogenic agent, pharmaceutical composition containing it and preparation method
09/09/2003US6616927 Processes for production of immunoglobulin A in milk
09/09/2003US6616925 Combined preparation for the treatment of neoplasic diseases or of infectious diseases
09/09/2003CA2244867C Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
09/09/2003CA2101648C Polysaccharide-protein conjugates
09/09/2003CA2062105C Purified mite allergen
09/04/2003WO2003073351A2 Screening process
09/04/2003WO2003073097A2 Methods for isolating ligands e.g. t cell epitopes
09/04/2003WO2003072800A2 Haemophilus adherence and penetration proteins
09/04/2003WO2003072799A2 Brother of the regulator of imprinted sites (boris)
09/04/2003WO2003072789A2 Microorganisms as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
09/04/2003WO2003072781A1 Mite galectin
09/04/2003WO2003072779A1 Method of using pituitary-specific genes
09/04/2003WO2003072771A2 Method of preparing a treatment product using a togaviridae expression construct
09/04/2003WO2003072766A1 Anti-ccr5 antibody
09/04/2003WO2003072740A2 Novel type-1 cytokine receptor glm-r
09/04/2003WO2003072736A2 Reagents and treatment methods for autoimmune diseases
09/04/2003WO2003072725A2 Recombinant negative strand virus rna expression systems and vaccines
09/04/2003WO2003072720A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
09/04/2003WO2003072719A2 Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences
09/04/2003WO2003072716A2 Sequence analysis of the tetravalent rotavirus vaccine
09/04/2003WO2003072715A2 Gasp1: a follistatin domain containing protein
09/04/2003WO2003072698A2 Surface proteins of leptospira
09/04/2003WO2003072608A1 Anti-human tenascin monoclonal antibody
09/04/2003WO2003072607A1 Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins
09/04/2003WO2003072603A2 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
09/04/2003WO2003072602A2 Protein complexes and methods for their use
09/04/2003WO2003072601A1 Method for producing hypoallergenic major birch pollen allergens rbet v 1
09/04/2003WO2003072599A2 Novel chemokine binding peptides capable of modulating the biological activity of chemokines
09/04/2003WO2003072598A2 Hsp70-derived peptides an uses thereof in the diagnosis and treatment of autoimmune diseases
09/04/2003WO2003072595A2 Methods and products based on oligomerization of stress proteins
09/04/2003WO2003072594A2 An obligate domain-swapped dimer of cyanovirin with enhanced anti-viral activity
09/04/2003WO2003072132A1 Adjuvant system for the production of antibodies, vaccine and use
09/04/2003WO2003072063A2 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
09/04/2003WO2003072062A2 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
09/04/2003WO2003072045A2 Treatment and prevention of aids progression and methods of using same
09/04/2003WO2003072044A2 Selection of poultry eimeria strains through extra-intestinal sporozoites
09/04/2003WO2003072040A2 Administration of agents for the treatment of inflammation
09/04/2003WO2003072036A2 Treatment methods using anti-cd22 antibodies
09/04/2003WO2003072035A2 Compositions and methods for the treatment of immune related diseases
09/04/2003WO2003072032A2 Sterile immunogenic non-tumorigenic tumor cell compositions and methods
09/04/2003WO2003072029A2 Methods of extending corneal graft survival
09/04/2003WO2003072018A2 Ricin vaccine and methods of making and using thereof
09/04/2003WO2003072017A2 Macromolecular conjugates and processes for preparing same
09/04/2003WO2003072016A2 Pharmaceutical compositions in particulate form
09/04/2003WO2003072012A2 Oral dna composition for hepatitis b virus chronic infection
09/04/2003WO2003071877A1 Compositions and methods for eliciting an immune response to gram-negative bacterial infections
09/04/2003WO2003064472A3 Treatment of ms with goat serum
09/04/2003WO2003057006A3 Use of antibodies against the muc18 antigen
09/04/2003WO2003054007A3 Streptococcus antigens
09/04/2003WO2003053462A3 Staphylococcus aureus exopolysaccharide and process
09/04/2003WO2003046560A3 Self-assembly molecules
09/04/2003WO2003030922A3 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
09/04/2003WO2003022867A3 Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
09/04/2003WO2003013647A3 Electrodes coated with treating agent and uses thereof
09/04/2003WO2003004525A8 Isolation and purification of plasmodium falciparum merozoite protein-142
09/04/2003WO2002101069A3 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
09/04/2003WO2002097395A3 P-cadherin as a target for anti-cancer therapy
09/04/2003WO2002097048A3 ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
09/04/2003WO2002089733A3 Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
09/04/2003WO2002082076A3 Renal cell carcinoma tumor markers
09/04/2003WO2002079248A3 Mammalian alpha-helical protein-53
09/04/2003WO2002079238A3 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis
09/04/2003WO2002074795A3 Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
09/04/2003WO2002072127A3 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof
09/04/2003WO2002060919A3 Molecules with extended half-lives, compositions and uses thereof
09/04/2003WO2002053775A3 Identification of genetic determinants of polymorphic cyp3a5 expression
09/04/2003WO2002052002A3 Immunomodulatory polynucleotides and methods of using the same
09/04/2003WO2002046426A3 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
09/04/2003WO2002046237A3 Humanized antibodies that recognize beta amyloid peptide
09/04/2003WO2002036807A3 Compositions and methods relating to breast specific genes and proteins
09/04/2003WO2002032943A9 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
09/04/2003WO2002020769A9 Human and mouse targeting peptides identified by phage display
09/04/2003WO2002016421A9 Altered ospa of borrelia burgdorferi
09/04/2003WO2002008456A3 Method for identifying metastatic tumor cells
09/04/2003WO2001066595A9 Human fgf-23 gene and gene expression products
09/04/2003US20030167502 Human monoclonal antibodies to dendritic cells
09/04/2003US20030166915 Retrovirus from the HIV group and its use
09/04/2003US20030166899 Antiinflammatory agents; antiarthritic agents; anticancer agents
09/04/2003US20030166897 Diagnosis, therapy cancer; transgenic animal
09/04/2003US20030166883 Genetic engineering; drug screening
09/04/2003US20030166875 Fibroblast growth factor homologous factor-2 and methods of use
09/04/2003US20030166872 Grafting antibodies to nucleic acids; anticancer agents, osteoporosis, vision defects, antiinflammatory agents, skin disorders
09/04/2003US20030166867 Fibrin nanoparticles and uses thereof
09/04/2003US20030166856 A set of open reading frames encoded with the template as the plus strand of the proviral DNA, and located in the region of HIV-1 long terminal repeat, and the genes encode a set of antisense proteins
09/04/2003US20030166853 Mucin peptide with immunoenhancing properties
09/04/2003US20030166851 Contacting a polypeptide (Transmembrane serin protease 9) with a substrate that is proteolytically cleaved by the polypeptide, adding a test compound, measuring the amount of substrate cleaved in the presence of test compound
09/04/2003US20030166849 A peptide of at least 5 amino acids containing a unique portion of a semaphorin, and such peptide has a semaphorin binding specificity
09/04/2003US20030166844 Immunologenic polypeptides; therapy for Streptococcus infections
09/04/2003US20030166832 Methods and compositions for impairing multiplication of HIV-1
09/04/2003US20030166601 Drug delivery of the nucleic acid into a target tissue or cell, comprising a core complex contains a nucleic acid and complex forming agents, fusion with cell membranes with nuclear uptake; polymeric outer shell
09/04/2003US20030166599 Uses of tgap7 for the modulation of leucocyte activation
09/04/2003US20030166589 Method and pharmaceutical composition for the treatment of multiple sclerosis
09/04/2003US20030166587 Compounds and methods for modulating activation of NF-kB
1 ... 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 ... 1823